Cytokines in bipolar disorder: Recent findings, deleterious effects but promise for future therapeutics

CNS Spectrums

Volumn 16, Issue 7, 2011, Pages 157-168

  Brietzke, Elisa ^a   Stabellini, Raquel ^a   Grassi Oliveira, Rodrigo ^b   Lafer, Beny ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CELECOXIB; CYTOKINE; HORMONE; LITHIUM; MESSENGER RNA; MONOAMINE; NEUROTRANSMITTER; NEUROTROPHIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VALPROIC ACID;

ALCOHOLISM; ARTICLE; AUTOIMMUNE DISEASE; BIPOLAR DISORDER; CELL LOSS; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMORBIDITY; CYTOKINE PRODUCTION; DEPRESSION; DISEASE ASSOCIATION; DRUG MECHANISM; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; GLIA CELL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOMODULATION; MANIA; MONOAMINE METABOLISM; MOOD DISORDER; NERVE CELL; NERVE CELL PLASTICITY; NEUROBIOLOGY; NEUROIMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE;

EID: 79960041660     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852912000338     Document Type: Article

References (174)

1. Gosselin D, Rivest S. Role of IL-1 and TNF in the brain: twenty years of progress on a Dr. Jekyll/Mr. Hyde duality of the innate immune system. Brain Behav Immun. 2007;21(3):281-289.
2. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2):201-217.
3. Marques AH, Cizza G, Sternberg E. Brain-immune interactions and implications in psychiatric disorders. Rev Bras Psiquiatr. 2007;29(Suppl 1):S27-S32.
4. Viljoen M, Panzer A. Proinflammatory cytokines: a common denominator in depression and somatic symptoms? Can J Psychiatry. 2005;50(2):128.
5. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157(5):683-694.
6. Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1355-1361.
7. Müller N, Schwarz MJ. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci. 2008;258(Suppl 2):97-106.
8. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63(8):801-808.
9. Thomas AJ, Davis S, Morris C, et al. Increase in interleukin-1beta in late-life depression. Am J Psychiatry. 2005;162(1):175-177.
10. Sinha S, Patil SA, Jayalekshmy V, et al. Do cytokines have any role in epilepsy? Epilepsy Res. 2008;82(2-3):171-176.
11. Shimommura Y, Shimizu H, Takahashi M, et al. Effects of peripheral administration of recombinant human interleukin-1 beta on feeding behavior of the rat. Life Sci. 1990;47(24):2185-2192.
12. Smith RS. The macrophage theory of depression. Med Hypotheses. 1991;35(4):298-306.
13. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56.
14. Orsal AS, Blois SM, Bermpohl D, et al. Administration of interferon-alpha in mice provokes peripheral and central modulation of immune cells, accompanied by behavioral effects. Neuropsychobiology. 2008;58(3-4):211-222.
15. Raison CL, Borisov AS, Majer M, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry. 2009;65(4):296-303.
16. Wirleitner B, Neurauter G, Schröcksnadel K, et al. Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem. 2003;10(16):1581-1591.
17. Wirleitner B, Rudzite V, Neurauter G, et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest. 2003;33(7):550-554.
18. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2004;164(9):1010-1014.
19. Pike JL, Irwin MR. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav Immun. 2006;20(2):169-174.
20. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999;4(4):317-327.
21. Wong ML, Dong C, Maestre-Mesa J, et al. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry. 2008;13(8):800-812.
22. Gold SM, Irwin MR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin North Am. 2009;29(2):309-320.
23. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732-741.
24. Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry. 2009;22(1):32-36.
25. Vaccarino V, Brennan ML, Miller AH, et al. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry. 2008;64(6):476-483.
26. Bremmer MA, Beekman AT, Deeg DJ, et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord. 2008;106(3):249-255.
27. Kim YK, Na KS, Shin KH, et al. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(5):1044-1053.
28. Kling MA, Alesci S, Csako G, et al. Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry. 2007;62(4):309-313.
29. Elenkov IJ, Iezzoni DG, Daly A, et al. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation. 2005;12(5):255-269.
30. Naarding P, Schoevers RA, Janzing JG, et al. A study on symptom profiles of late-life depression: the influence of vascular, degenerative and inflammatory risk-indicators. J Affect Disord. 2005;88(2):155-162.
31. Grassi-Oliveira R, Brietzke E, Pezzi JC, et al. Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder. Psychiatry Clin Neurosci. 2009;63(2):202-820.
32. McCaffery JM, Frasure-Smith N, Dube MP, et al. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med. 2006;68(2):187-200.
33. Danese A, Moffitt TE, Pariante CM, et al. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry. 2008;65(4):409-415.
34. Pace TW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163(9):1630-1633.
35. Miller GE, Rohleder N, Stetler C, et al. Clinical depression and regulation of the inflammatory response during acute stress. Psychosom Med. 2005;67(5):679-687.
36. Kim YK, Lee SW, Kim SH, et al. Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):356-361.
37. Eller T, Vasar V, Shlik J, et al. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):445-450.
38. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293(20):2528-2530.
39. McIntyre RS, Soczynska JK, Beyer JL, et al. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry. 2007;20(4):406-416.
40. Zarate CA Jr, Tohen M, Land M, et al. Functional impairment and cognition in bipolar disorder. Psychiatr Q. 2000;71(4):309-329.
41. Sanchez-Moreno J, Martinez-Aran A, Tabarés-Seisdedos R, et al. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom. 2009;78(5):285-297.
42. Bachmann RF, Schloesser RJ, Gould TD, et al. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol. 2005;32(2):173-202.
43. Schloesser RJ, Huang J, Klein PS, et al. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 2008;33(1):110-133.
44. Schloesser RJ, Chen G, Manji HK. Neurogenesis and neuroenhancement in the pathophysiology and treatment of bipolar disorder. Int Rev Neurobiol. 2007;77:143-178.
45. Quiroz JA, Gray NA, Kato T, et al. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 2008;33(11):2551-2565
46. Sanacora G. New understanding of mechanisms of action of bipolar medications. J Clin Psychiatry. 2008;69(Suppl 5):22-27.
47. Le-Niculescu H, Kurian SM, Yehyawi N, et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry. 2009;14(2):156-174.
48. Pan W, Kastin AJ. Penetration of neurotrophins and cytokines across the blood-brain/blood-spinal cord barrier. Adv Drug Deliv Rev. 1999;36(2-3):291-298.
49. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007;21(4):374-383.
50. Pasic J, Levy WC, Sullivan MD. Cytokines in depression and heart failure. Psychosom Med. 2003;65(2):181-193.
51. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev. 2009;33(3):355-366.
52. Pickering M, O'Connor JJ. Pro-inflammatory cytokines and their effects in the dentate gyrus. Prog Brain Res. 2007;163:339-354.
53. Baier PC, May U, Scheller J, et al. Impaired hippocampus-dependent and-independent learning in IL-6 deficient mice. Behav Brain Res. 2009;200(1):192-196.
54. Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A. 2008;105(2):751-756.
55. Ben Menachem-Zidon O, Goshen I, Kreisel T, et al. Intrahippocampal transplantation of transgenic neural precursor cells overexpressing interleukin-1 receptor antagonist blocks chronic isolation-induced impairment in memory and neurogenesis. Neuropsychopharmacology. 2008;33(9):2251-2262.
56. Barrientos RM, Sprunger DB, Campeau S, et al. Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neuroscience. 2003;121(4):847-853.
57. Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res. 2007;85(10):2059-2070.
58. Macdonald NJ, Delderfield SM, Zhang W, et al. Tumor necrosis factor-alpha-vs. growth factor deprivation-promoted cell death: distinct converging pathways. Aging Cell. 2003;2(5):245-256.
59. Mattson MP, Meffert MK. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006;13(5):852-860.
60. Tramontina JF, Andreazza AC, Kauer-Sant'anna M, et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett. 2009;452(2):111-113.
61. Kapczinski F, Dias VV, Frey BN, et al. Brain-derived neurotrophic factor in bipolar disorder: beyond trait and state: comment on 'Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders'. Bipolar Disord. 2009;11(2):221-2; author reply 222-223.
62. Kapczinski F, Dal-Pizzol F, Teixeira AL, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res. 2011;45(2):156-161.
63. Kapczinski F, Frey BN, Andreazza AC, et al. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr. 2008;30(3):243-245.
64. Kauer-Sant'Anna M, Tramontina J, Andreazza AC, et al. Traumatic life events in bipolar disorder: impact on BDNF levels and psychopathology. Bipolar Disord. 2007;9(Suppl 1):128-135.
65. Cunha AB, Frey BN, Andreazza AC, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett. 2006;398(3):215-219.
66. Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078-1090.
67. Kim YK, Jung HG, Myint AM, et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1-3):91-95.
68. Ortiz-Dominguez A, Hernandez ME, Berlanga C, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596-602.
69. O'Brien SM, Scully P, Scott LV, et al. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2-3):263-267.
70. Brietzke E, Stertz L, Fernandes B, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214-217.
71. Boufidou F, Nikolaou C, Alevizos B, et al. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord. 2004;82(2):309-313.
72. Brietzke E, Kauer-Sant'anna M, Teixeira AL, et al. Abnormalities in serum chemokine levels in euthymic patients with Bipolar Disorder. Brain Behav Immun. 2009;23(8):1079-1082.
73. Takahashi K, Funata N, Ikuta F, et al. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J Neuroinflammation. 2008;5:11.
74. Pae CU, Lee KU, Han H, et al. Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. Psychiatry Res. 2004;125(1):65-68.
75. Papiol S, Rosa A, Gutiérrez B, et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J Med Genet. 2004;41(3):219-223.
76. Czerski PM, Rybakowski F, Kapelski P, et al. Association of tumor necrosis factor-308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology. 2008;57(1-2):88-94.
77. Papiol S, Molina V, Desco M, et al. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13). Genes Brain Behav. 2008;7(7):796-801.
78. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 2008;65(4):395-407.
79. Rao JS, Harry GJ, Rapoport SI, et al. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15(4):384-392.
80. Kobayashi H. Endogenous anti-inflammatory substances, inter-alpha-inhibitor and bikunin. Biol Chem. 2006;387(12):1545-1549.
81. Scott LJ, Muglia P, Kong XQ, et al. Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci U S A. 2009;106(18):7501-7506.
82. Hyun M, Friedman SD, Dunner DL. Relationship of childhood physical and sexual abuse to adult bipolar disorder. Bipolar Disord. 2000;2(2):131-135.
83. Leverich GS, Post RM. Course of bipolar illness after history of childhood trauma. Lancet. 2006;367(9516):1040-1042.
84. Garno JL, Goldberg JF, Ramirez PM, et al. Impact of childhood abuse on the clinical course of bipolar disorder. Br J Psychiatry. 2005;186:121-125.
85. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci. 2002;966:290-303.
86. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15(3):199-226.
87. Danese A, Pariante CM, Caspi A, et al. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci U S A. 2007;104(4):1319-1324.
88. Widom CS, DuMont K, Czaja SJ. A prospective investigation of major depressive disorder and comorbidity in abused and neglected children grown up. Arch Gen Psychiatry. 2007;64(1):49-56.
89. Dong M, Giles WH, Felitti VJ, et al. Insights into causal pathways for ischemic heart disease: adverse childhood experiences study. Circulation. 2004;110(13):1761-1766.
90. Dube SR, Felitti VJ, Dong M, et al. The impact of adverse childhood experiences on health problems: evidence from four birth cohorts dating back to 1900. Prev Med. 2003;37(3):268-277.
91. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102(30):10604-10609.
92. Quraishi S, Frangou S. Neuropsychology of bipolar disorder: a review. J Affect Disord. 2002;72(3):209-226.
93. de Almeida Rocca CC, de Macedo-Soares MB, Gorenstein C, et al. Social dysfunction in bipolar disorder: pilot study. Aust N Z J Psychiatry. 2008;42(8):686-692.
94. Olley A, Malhi GS, Mitchell PB, et al. When euthymia is just not good enough: the neuropsychology of bipolar disorder. J Nerv Ment Dis. 2005;193(5):323-330.
95. Bruel-Jungerman E, Davis S, Laroche S. Brain plasticity mechanisms and memory: a party of four. Neuroscientist. 2007;13(5):492-505.
96. Bruel-Jungerman E, Rampon C, Laroche S. Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses. Rev Neurosci. 2007;18(2):93-114.
97. Bruel-Jungerman E, Davis S, Rampon C, et al. Long-term potentiation enhances neurogenesis in the adult dentate gyrus. J Neurosci. 2006;26(22):5888-5893.
98. Bruel-Jungerman E, Laroche S, Rampon C. New neurons in the dentate gyrus are involved in the expression of enhanced long-term memory following environmental enrichment. Eur J Neurosci. 2005;21(2):513-521.
99. Schneider H, Pitossi F, Balschun D, et al. A neuromodulatory role of interleukin-1beta in the hippocampus. Proc Natl Acad Sci U S A. 1998;95(13):7778-7783.
100. Rachal Pugh C, Fleshner M, Watkins LR, et al. The immune system and memory consolidation: a role for the cytokine IL-1beta. Neurosci Biobehav Rev. 2001;25(1):29-41.
101. Goshen I, Kreisel T, Ounallah-Saad H, et al. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology. 2007;32(8-10):1106-1115.
102. Marsland AL, Gianaros PJ, Abramowitch SM, et al. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry. 2008;64(6):484-490.
103. Marsland AL, Petersen KL, Sathanoori R, et al. Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosom Med. 2006;68(6):895-903.
104. Hryniewicz A, Bialuk I, Kaminski KA, et al. Impairment of recognition memory in interleukin-6 knock-out mice. Eur J Pharmacol. 2007;577(1-3):219-320.
105. Myint AM, Schwarz MJ, Steinbusch HW, et al. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis. 2009;24(1):55-68.
106. Maccioni RB, Rojo LE, Fernandez JA, et al. The role of neuroimmunomodulation in Alzheimer's disease. Ann N Y Acad Sci. 2009;1153:240-246.
107. Giunta S. Exploring the complex relations between inflammation and aging (inflamm-aging): anti-inflamm-aging remodelling of inflamm-aging, from robustness to frailty. Inflamm Res. 2008;57(12):558-563.
108. Khairova RA, Machado-Vieira R, Du J, et al. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2009;12(4):561-578.
109. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15(1):4-9.
110. Kyrtsonis MC, Maltezas D, Tzenou T, et al. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol. 2009;46(2):110-117.
111. Kameyama K, Takahashi M, Ohata K, et al. Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution. J Thorac Cardiovasc Surg. 2009;137(5):1180-1184.
112. Blechacz BR, Sanchez W, Gores GJ. A conceptual proposal for staging ductal cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25(3):238-239.
113. Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand. 1993;87(4):225-230.
114. McGorry PD, Purcell R, Hickie IB, et al. Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust. 2007;187(7 Suppl):S40-S42.
115. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course pecifier: a bipolar disorder perspective. J Affect Disord. 2007;100(1-3):279-281.
116. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early-vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12(4):447-458.
117. Andreazza AC, Kauer-Sant'anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111(2-3):135-144.
118. Berk M, Conus P, Lucas N, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9(7):671-678.
119. Kempton MJ, Geddes JR, Ettinger U, et al. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry. 2008;65(9):1017-1032.
120. Zanetti MV, Schaufelberger MS, de Castro CC, et al. White-matter hyperintensities in first-episode psychosis. Br J Psychiatry. 2008;193(1):25-30.
121. Beaulieu C. The basis of anisotropic water diffusion in the nervous system-a technical review. NMR Biomed. 2002;15(7-8):435-455.
122. Jones DK. Studying connections in the living human brain with diffusion MRI. Cortex. 2008;44(8):936-952.
123. McDonald C, Bullmore ET, Sham PC, et al. Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch Gen Psychiatry. 2004;61(10):974-984.
124. Adler CM, Holland SK, Schmithorst V, et al. Abnormal frontal white matter tracts in bipolar disorder: a diffusion tensor imaging study. Bipolar Disord. 2004;6(3):197-203.
125. Beyer JL, Taylor WD, MacFall JR, et al. Cortical white matter microstructural abnormalities in bipolar disorder. Neuropsychopharmacology. 2005;30(12):2225-2229.
126. Bruno S, Cercignani M, Ron MA. White matter abnormalities in bipolar disorder: a voxel-based diffusion tensor imaging study. Bipolar Disord. 2008;10(4):460-468.
127. Zanetti MV, Jackowski MP, Versace A, et al. State-dependent microstructural white matter changes in bipolar I depression. Eur Arch Psychiatry Clin Neurosci. 2009;259(6):316-328.
128. Karlsgodt KH, van Erp TG, Poldrack RA, et al. Diffusion tensor imaging of the superior longitudinal fasciculus and working memory in recent-onset schizophrenia. Biol Psychiatry. 2008;63(5):512-518.
129. Lindquist S, Bodammer N, Kaufmann J, et al. Histopathology and serial, multimodal magnetic resonance imaging in a multiple sclerosis variant. Mult Scler. 2007;13(4):471-482.
130. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry. 2008;69(4):514-519.
131. McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006;57(8):1140-1144.
132. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care. 2007;13(7 Suppl):S170-S177.
133. Sicras A, Rejas J, Navarro R, et al. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord. 2008;10(5):607-616.
134. Soreca I, Fagiolini A, Frank E, et al. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res. 2008;42(11):956-961.
135. Satoh M, Minami Y, Takahashi Y, et al. Immune modulation: role of the inflammatory cytokine cascade in the failing human heart. Curr Heart Fail Rep. 2008;5(2):69-74.
136. Werba JP, Veglia F, Amato M, et al. Patients with a history of stable or unstable coronary heart disease have different acute phase responses to an inflammatory stimulus. Atherosclerosis. 2008;196(2):835-840.
137. Vinten-Johansen J, Jiang R, Reeves JG, et al. Inflammation, proinflammatory mediators and myocardial ischemia-reperfusion Injury. Hematol Oncol Clin North Am. 2007;21(1):123-145.
138. Cohen-Kashi Malina K, Cooper I, Teichberg VI. Closing the gap between the in-vivo and in-vitro blood brain barrier tightness. Brain Res. 2009;1284:12-21.
139. Friedman A, Kaufer D, Heinemann U. Blood-brain barrier breakdown-inducing astrocytic transformation: Novel targets for the prevention of epilepsy. Epilepsy Res. 2009;85(2-3):142-149.
140. Nakagawa S, Deli MA, Kawaguchi H, et al. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int. 2009;54(3-4):253-263.
141. Wolburg H, Noell S, Mack A, et al. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res. 2009;335(1):75-96.
142. Lee SW, Kim WJ, Choi YK, et al. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med. 2003;9(7):900-906.
143. Rieckmann P, Engelhardt B. Building up the blood-brain barrier. Nat Med. 2003;9(7):828-829.
144. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6(3):219-233.
145. Toro CT, Hallak JE, Dunham JS, et al. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci Lett. 2006;404(3):276-281.
146. Frey BN, Andreazza AC, Ceresér KM, et al. Evidence of astrogliosis in rat hippocampus after d-amphetamine exposure. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(7):1231-1234.
147. Webster MJ, O'Grady J, Kleinman JE, et al. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience. 2005;133(2):453-461.
148. Knijff EM, Breunis MN, Kupka RW, et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9(7):743-753.
149. Rapaport MH, Manji HK. The effects of lithium on ex vivo cytokine production. Biol Psychiatry. 2001;50(3):217-224.
150. Jaffee WB, Griffin ML, Gallop R, et al. Depression precipitated by alcohol use in patients with co-occurring bipolar and substance use disorders. J Clin Psychiatry. 2009;70(2):171-176.
151. Cardoso BM, Kauer Sant'Anna M, Dias VV, et al. The impact of co-morbid alcohol use disorder in bipolar patients. Alcohol. 2008;42(6):451-457.
152. Neves FS, Malloy-Diniz LF, Correa H. Suicidal behavior in bipolar disorder: what is the influence of psychiatric comorbidities? J Clin Psychiatry. 2009;70(1):13-18.
153. Tiwari V, Kuhad A, Chopra K. Suppression of neuro-inflammatory signaling cascade by tocotrienol can prevent chronic alcohol-induced cognitive dysfunction in rats. Behav Brain Res. 2009;203(2):296-303.
154. Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol. 2009;50(6):1258-1266.
155. Vallés SL, Blanco AM, Pascual M, et al. Chronic ethanol treatment enhances inflammatory mediators and cell death in the brain and in astrocytes. Brain Pathol. 2004;14(4):365-371.
156. Diaz FJ, James D, Botts S, et al. Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression. Bipolar Disord. 2009;11(2):154-165.
157. Ostacher MJ, Nierenberg AA, Perlis RH, et al. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry. 2006;67(12):1907-1911.
158. Glossop JR, Dawes PT, Mattey DL. Association between cigarette smoking and release of tumour necrosis factor alpha and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology. 2006;45(10):1223-1229.
159. Sapey E, Ahmad A, Bayley D, et al. Imbalances Between Interleukin-1 and Tumor Necrosis Factor Agonists and Antagonists in Stable COPD. J Clin Immunol. 2009;29(4):508-516.
160. Csiszar A, Podlutsky A, Wolin MS, et al. Oxidative stress and accelerated vascular aging: implications for cigarette smoking. Front Biosci. 2009;14:3128-3144.
161. Domagala-Kulawik J. Effects of cigarette smoke on the lung and systemic immunity. J Physiol Pharmacol. 2008;59(Suppl 6):19-34.
162. Halvorsen B, Lund Sagen E, Ueland T, et al. Effect of smoking cessation on markers of inflammation and endothelial cell activation among individuals with high risk for cardiovascular disease. Scand J Clin Lab Invest. 2007;67(6):604-611.
163. Whetzel CA, Corwin EJ, Klein LC. Disruption in Th1/Th2 immune response in young adult smokers. Addict Behav. 2007;32(1):1-8.
164. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23(2):87-94.
165. Soczynska JK, Kennedy SH, Goldstein BI, et al. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: Novel hypothesis-driven treatments for bipolar depression? Neurotoxicology. 2009;30(4):497-521.
166. Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short-and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther. 2005;22(2):101-110.
167. Tookman AJ, Jones CL, DeWitte M, et al. Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Support Care Cancer. 2008;16(10):1131-1140.
168. Minderhoud IM, Samsom M, Oldenburg B. Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol. 2007;13(14):2089-2093.
169. Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008;103(12):3132-3141.
170. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29-35.
171. Krishnan R, Cella D, Leonardi C, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol. 2007;157(6):1275-1277.
172. Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health. 2008;11(3):400-407.
173. Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation. 2008;5:3.
174. Mandreakar-Colucci S, Landreth GE. Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2010;9(2):156-167.